Athira Pharma

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

There was a big shakeup in the biotech's C-suite.

Why Athira Pharma Crashed Today

PULLMAN, Wash., June 18, 2021 /PRNewswire/ -- Washington State University announced today that it has undertaken a review of claims of potential research misconduct involving research conducted by Leen Kawas, a former WSU student and current president and chief executive officer of Athira Pharma, Inc. (NASDAQ: ATHA).

Washington State University to review claims of research misconduct

New York, New York--(Newsfile Corp. - June 18, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) common stock.Athira is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira's lead drug candidate is ATH-1017 which is used to treat Alzheimer's and Parkinson's dementia. Athira conducted an initial public offering of its common...

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Athira Pharma, Inc. (ATHA) Common Stock

Boston, Massachusetts--(Newsfile Corp. - June 18, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential violations of the federal securities laws by Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Athira, formerly known as M3 Biotechnology, Inc., is a biopharmaceutical company based in Bothell, Washington. On September 22, 2020, the Company closed its initial public offering, in which the Company sold and issued 12,000,000 shares of common stock...

Berman Tabacco Investigates Potential Securities Claims Against Athira Pharma, Inc. (ATHA)

Athira Pharma Inc (NASDAQ: ATHA) CEO Leen Kawas has been placed on temporary leave until the company completes a review “stemming from doctoral research Dr. Kawas conducted while at Washington State University.” The 10-year-old company, which is developing drugs for treating Alzheimer's disease, said that Chief Operating Officer Mark Litton would assume day-to-day responsibilities during Kawas' leave.

Athira Pharma Stock Plummets After CEO Placed On Temporary Leave

The stock price of Athira Pharma Inc (NASDAQ: ATHA) fell by over 25% pre-market. This is why it happened.

ATHA Stock Price Falls Over 25% Pre-Market: Why It Happened

Athira Pharma CEO Leen Kawas has been placed on temporary leave until the Seattle area biotechnology company completes a review “stemming from doctoral research Dr.

Athira Pharma CEO placed on leave, shares plummet

Leen Kawas Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University Leen Kawas Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University

Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company

Biogen

The approval on Monday of the first new drug for Alzheimer's disease in nearly two decades — Biogen's aducanumab — helps shine a light on a path forward for other companies developing Alzheimer's therapies, including Seattle-based Athira Pharma, which saw its stock rise more than 4% off the Biogen news.

Approval of Biogen's drug for Alzheimer's disease may ease path for others such as Athira Pharma

-Phase 2 trial initiation for Parkinson's disease dementia program and IND submission for neuropsychiatric program planned by end of 2021-

Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights

Athira Pharma, Inc. (ATHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Athira Pharma, Inc. (ATHA) Upgraded to Buy: Here's What You Should Know

BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum. The panel, titled “Progress in Alzheimer's and Dementia,” will be aired on Wednesday, April 28, 2021, at 8:30 a.m. PT /11:30 a.m. ET.

Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum

BOTHELL, Wash., April 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will host an educational webinar on targeting HGF/MET, a naturally occurring, neuronal repair pathway. The live webinar event will be on Thursday, April 15, at 1:30 p.m. PT / 4:30 p.m.ET.

Athira Pharma to Host Educational Webinar on Targeting HGF/MET: A Naturally Occurring Neuronal Repair Pathway

– LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling patients –

Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

BOTHELL, Wash., March 24, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Conference on Thursday, April 1, 2021, at 9:00 am ET.

Athira Pharma to Present at Stifel's 3rd Annual CNS Conference

American Well Corporation

Broadstone Net Lease

COMPASS Pathways

Coupang

Dyne Therapeutics

GreenBox POS

908 Devices

Metacrine

Outset Medical

Poshmark

Pactiv Evergreen

StepStone Group

Sumo Logic

Vitru Limited

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.

U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week

BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Barbara Kosacz to its Board of Directors. Ms. Kosacz is Chief Operating Officer and General Counsel at Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that transform the lives of those affected by cancer.

Athira Pharma Announces Appointment of Barbara Kosacz to its Board of Directors

BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a corporate overview during the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.

Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference

ARCA biopharma

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed the share prices near or above the liquidation value. Should the company fail, these shareholders would, in theory, still be able to make money due to a difference between the liquidation value and purchasing price.

3 Net-Net Working Capital Stocks

BOTHELL, Wash., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 600,000 shares of common stock at the public offering price of $22.50 per share, less underwriting discounts and commissions. Including proceeds from the sale of the additional shares, Athira received total gross proceeds of $103.5 million from the public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira. The closing of the sale of the additional shares occurred today.

Athira Pharma Announces Exercise of Underwriters' Option to Purchase Additional Shares

Intel

Teledyne Technologies

Alcoa

Armata Pharmaceuticals Inc

Fastenal

FuelCell Energy

Green Brick Partners

B. Riley Financial

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets.

Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More

The clinical-stage biopharma company announced the pricing of a public stock offering.

Why Athira Pharma Stock Dropped Today

BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $22.50 per share. All of the shares of common stock are being offered by Athira. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira, are expected to be $90.0 million. The offering is expected to close on January 25, 2021, subject to satisfaction of customary closing conditions. In addition, Athira has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price less underwriting discounts and commissions.

Athira Pharma Announces Pricing of Public Offering of Common Stock

BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Athira. In addition, Athira expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

Athira Pharma Announces Proposed Public Offering of Common Stock

Athira is a recent IPO with early but interesting data in AD. They will provide data from a potentially pivotal phase 2/3 trial in end-2022.

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

News for Athira Pharma Stock (ATHA)